Dr. Christopher John Ong

Dr. Christopher John Ong

B.Sc. University of British Columbia, 1988
Ph.D. University of British Columbia, 1996

Team: 
Clinical and Research Scientists
Positions: 

Senior Research Scientist, Vancouver Prostate Centre
Associate Professor, Department of Urologic Sciences, University of British Columbia

 

A key area of focus of Dr. Ong's research program is to understand the molecular mechanisms that govern prostate cancer growth and treatment resistance.  His primary focus has been focused on defining and targeting cell signalling pathways underlying the development and progression of prostate cancer and to develop new therapeutic strategies to improve survival.  Dr. Ong and colleagues have recently discovered a critical secreted cell signaling protein called SEMA3C that drives cancer growth. From this discovery, they developed a novel protein-based medication that disrupts SEMA3C signaling and prevents unhealthy cell growth that leads to prostate cancer, and potentially other cancers.

Dr. Ong is also a co-discoverer/inventor of a novel class of small molecule agonists of the SH2-containing inositol phosphatase, SHIP. This technology was licensed to Aquinox Pharmaceuticals, a UBC spin-off company that Dr. Ong co-founded with his colleagues, Drs. Mui, Andersen and Krystal. Aquinox’s lead drug candidate, Rosiptor, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Building upon the positive Phase 2 trial results where AQX-1125 demonstrated an ability to improve both pain and urinary symptoms in patients with Interstitial Cystitis Bladder Pain Syndrome (IC/BPS), Rosiptor is now in multicenter Phase 3 clinical trials for treatment of IC/BPS.  Top-line data from the LEADERSHIP 301 trial is anticipated in the third quarter of 2018. 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 

Employment

Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov